This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fox, R. Search for Related Content PubMed PubMed Citation Articles by Fox, R. Social Bookmarking                         What's this?

Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development

Division of Rheumatology, Scripps Clinic and Research Foundation, La Jolla, California

A wide variety of mechanisms of anti-rheumatic action have been proposed for anti malarial agents. The molecular actions of chloroquine have been most thoroughly studied in vitro and in vivo, but it is likely that hydroxychloroquine works by a similar mechanism. Both agents are weak diprotic bases that can pass through the lipid cell membrane and preferentially concentrate in acidic cyto-plasmic vesicles. The resulting slight elevation of pH within these vesicles in macrophages or other antigen-presenting cells may influence the immune response to autoantigens. We hypothesize that anti-malarial agents influence the association of autoantigenic peptides with class II MHC molecules in the compartment for peptide loading and/or the subsequent processing and transport of the peptide-MHC complex to the cell membrane. This model of anti-malarial action provides a method to test additional drugs for their ability to modulate the immune response.

Key Words: anti-malarial • chloroquine • hydroxychloroquine

Lupus, Vol. 5, No. 1 suppl, S4-S10 (1996)
DOI: 10.1177/096120339600500103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G Ruiz-Irastorza and M. Khamashta Hydroxychloroquine: the cornerstone of lupus therapy Lupus, April 1, 2008; 17(4): 271 - 273. [PDF]

				C.S. Patil and K.L. Kirkwood p38 MAPK Signaling in Oral-related Diseases Journal of Dental Research, September 1, 2007; 86(9): 812 - 825. [Abstract] [Full Text] [PDF]

				G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus, September 1, 2006; 15(9): 577 - 583. [Abstract] [PDF]

				A Wozniacka, I Cygankiewicz, M Chudzik, A Sysa-Jedrzejowska, and J. Wranicz The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia, Heart Rate Variability and Repolarization Parameters Lupus, August 1, 2006; 15(8): 521 - 525. [Abstract] [PDF]

				A Wozniacka, A Carter, and D P Mccauliffe Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit Lupus, February 1, 2002; 11(2): 71 - 81. [Abstract] [PDF]

				R A Levy, V S Vilela, M J Cataldo, R C Ramos, J L. Duarte, B R Tura, E M. Albuquerque, and N R Jesus Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study Lupus, June 1, 2001; 10(6): 401 - 404. [Abstract] [PDF]